Project Grant R43HL180089
Award Date 9/5/25
Completion Date 2/28/27
Dollars Obligated $321K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44121, USA
Similar Awards
- The $784,203 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting the development and testing of a small, durable, and hemocompatible centrifugal blood pump for use in children aged 1-11 years (weighing approximately 10-35 kg) with heart failure. The immediate goal is to test and refine the "PSU Child VAD" (ventricular assist device) prototype through a series of 30-day in-vivo studies to validate the design...
- This Project Grant award from the National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a bearingless flux reversal motor for a neonatal and pediatric extracorporeal life support application. The $870,467 award to Ension Inc. aims to address shortcomings of the currently available pediatric blood pump, the Abbott Pedimag, by developing an innovative bearingless (magnetically levitated) motor...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- The National Heart, Lung, and Blood Institute (NHLBI), under the federal Cardiovascular Diseases Research program (CFDA 93.837), awarded a $306,643 project grant to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed to efficiently accommodate the low flow rates needed for pediatric and neonatal patients. The project aims to design, develop, and test a low-flow ECMO pump capable of operating at flow rates from 0.05 to 0.5 L/min, which is an order of...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,024,635 project grant to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to reduce complications and enhance quality of life for heart failure patients by eliminating the need for a percutaneous driveline and external power supply. The key innovation is a hybrid magnetically levitated blood pump that requires...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This $321,679 Project Grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and testing of an expandable pediatric pulmonary heart valve device. The research aims to create a valve that can grow larger with the patient to address the challenge of multiple open-heart surgeries required for infants and children with severe heart valve defects. The key research activities include optimizing the...
- This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $709,718 Project Grant to Florida International University (FIU) on September 1, 2025. The objective of this award is to develop methods for storing and preserving living valvular allografts (tissue transplants) ex vivo, to maintain their viability and availability for cardiac valve transplantation procedures. The project aims to integrate a preservation solution...